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P-glycoprotein (P-gp) confers cross-resistance to a variety of
structurally unrelated cytotoxic drugs, e.g. epidophyllotoxins,
vinca alkaloids, anthracyclines, taxanes and actinomycin D
(Endicott and Ling, 1989). P-gp is a member of the ATP-binding
cassette transporter family and is able to efflux cytotoxic drugs
against a concentration gradient, therefore causing a cellular drug
accumulation deficit, resulting in resistance. This active transport
requires the hydrolysis of ATP (Gottesman and Pastan, 1993) and
can be reversed in vitro by a broad range of compounds which
are structurally unrelated and non-cytotoxic, e.g. verapamil,
cyclosporin A, quinidine, trifluaperazine, tamoxifen and many
more (Ford and Hait, 1990).
Clinical studies have shown some benefit using the weak P-gp
inhibitor verapamil in addition to chemotherapy in malignant
lymphomas (Miller et al, 1991) or cyclosporin A in multiple
myeloma (Sonneveld et al, 1992). Serious side-effects occurring at
P-gp inhibitor concentrations required to fully reverse resistance in
vitro precluded widespread use of these modulators. Therefore, the
development of potent P-gp inhibitors that are better tolerated,
remains an important task in successfully overcoming multidrug
resistance.
GF120918 (also called GG918/GW0918), an acridonecarbox-
amide derivative, has been identified as a new potent P-gp
inhibitor (Hyafil et al, 1993). At a concentration of 20 nM, activity
was consistently achieved in vitro and GF120918 was found to be
100-fold more potent than verapamil (Hyafil et al, 1993). In vivo a
single dose of GF120918 sensitized mice inoculated intraperi-
toneally with P-gp expressing xenografts (P388/Dox leukaemia or
C26 colon carcinoma) to doxorubicin (Hyafil et al, 1993).
In the experiments reported in this paper we investigate the
ability of GF120918 to sensitize the P-gp-expressing human
Muellerian uterine sarcoma cell line MES-Dx5, which had been
selected in increasing doxorubicin concentrations up to 500 nM
(Harker and Sikic, 1985).
Few examples of detailed pharmacological analysis of the
potency of P-gp inhibitors to modulate resistance to various
cytotoxic drugs exist. One such example is the characterization of
the potency of CP100 356 by Kajiji et al (1994). In the series of
experiments described, detailed quantitative efforts have been
made to determine inhibitor properties of GF120918 since these
results could have bearing on the design of future clinical trials
with P-gp inhibitors.
MATERIALS AND METHODS
Materials
McCoy’s 5A cell culture medium was purchased from Sigma
(Poole, UK) and all other cell culture reagents from Gibco-BRL
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(Paisley, UK). MES-SA and MES-Dx5 were obtained from the
American Type Tissue Culture Collection (Rockville, MD, USA)
and MCF-7/ADR cells from the European Collection of Cell
Culture (Salisbury, UK). [3H]-vinblastine (11.4–13.5 Ci mmol–1
and [14C]-doxorubicin (60 mCi mmol–1) were purchased from
Amersham (Little Chalfont, UK). [3H]-taxol (19.3 Ci mmol–1) was
obtained from the National Cancer Institute (Bethesda, MD,
USA). [3H]-taxol and [14C]-doxorubicin were aliquoted and not
frozen after thawing. Doxorubicin, etoposide, taxol, vinblastine
and cyclosporin A were supplied by Sigma (Poole, UK). Taxotere
was a gift from Rhône-Poulenc Rorer (Paris, France). Verapamil
and GF120918 (Figure 1) were supplied by GlaxoWellcome
(USA). CP100356 was a gift from Dr Kajiji, Pfizer (Groton, CT,
USA), Dexniguldepine from Raine Boer, Byk-Gulden Lomberg
GmBH (Konstanz, Germany), CGP41251 from Professor Gescher,
MRC Toxicology Unit (Leicester, UK) and PSC833 from Sandoz
(Basel, Switzerland). Stock solutions of drugs were made up in
dimethyl sulphoxide (DMSO) at a concentration of 10 mM and
stored at –20°C. Materials used for Western blotting were: mono-
clonal antibody NCL-JSB-1 from Novocastra Laboratories Ltd
(Peterborough, UK), mouse peroxidase IgG from Sigma (Poole,
UK) and enhanced chemiluminescence (ECL) protein detection
reaction from Amersham (Little Chalfont, UK). Protein concentra-
tions were measured with the Bio-Rad Protein Assay, Bio-Rad
Laboratories Ltd (Hemel Hempstead, UK). All other reagents
were of the highest available purity obtained from commercial
sources.
Cell culture
MES-SA cells and the doxorubicin-selected clone MES-Dx5
(Harker et al, 1983; Harker and Sikic, 1985) were grown as a
monolayer in McCoy’s 5A medium supplemented with 10% fetal
calf serum (FCS), 20 000 U penicillin and 20 mg streptomycin per
litre. The P-gp expressing MCF-7/ADR cells, derived from a
human breast cancer cell line were grown as a monolayer in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FCS, 20 000 U penicillin and 20 mg streptomycin per
litre as previously described (Ferry et al, 1995). Fifty per cent FCS
was employed in experiments assessing the effect of protein
binding. The cells were maintained in a humidified atmosphere
containing 5% carbon dioxide at 37°C. All cell lines were
mycoplasma-negative.
Cytotoxicity assay
The tetrazolium dye based MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) assay (Mosmann, 1983) was
used to assess cytotoxicity. MES-SA or MES-Dx5 cells were
seeded into flat-bottom 96-well plates at 2000 cells per well and
grown for 24 h in drug-free medium. Cells were incubated for 72 h
with cytotoxic agents ± GF120918. A total of 20 ml of MTT dye
(5 mg ml–1 phosphate-buffered saline (PBS)) was added and
incubated for 4 h at 37°C. All medium was removed and the
formazan crystals dissolved in 100 ml DMSO. The absorption was
measured in a spectrophotometer at a wavelength of 550 nm.
Radiolabelled drug accumulation assay
Drug accumulation assays were performed as previously described
(Ferry et al, 1995). Briefly, 80 ´ 104 MES-SA or MES-Dx5 cells
ml–1 were plated into each well of a 12-well plate and incubated for
24 h. McCoy’s 5A medium was replaced with 1 ml uptake
medium per well (McCoy’s 5A medium without supplements and
added 5 mM glucose and 5 mM magnesium chloride (MgCl2)). The
cells were incubated in a shaking waterbath at 37°C in near
darkness. GF120918 (1 mM) in 10 ml of DMSO or 10 ml DMSO for
the control were added to each well. [3H]-vinblastine (» 1n M),
[3H]-taxol (» 0.5 nM) or [14C]-doxorubicin (» 20 nM) were added
at a volume of 10 ml per well which commenced the assay and
incubated for 30 min to 4 h at 37°C. The reaction was stopped
by removal of the uptake medium and addition of 1 ml liquid
scintillant. Radioactivity was quantitated by liquid scintillation
counting.
Preparation of cell surface membranes
MES-SA and MES-Dx5 cell surface membranes were prepared by
a method as previously described (Ferry et al, 1992). Ten 80 cm2
flasks of cells were grown to confluence (equivalent to 5 ´ 108
cells). After removal of medium and addition of ice-cold buffer
A (50 mM Tris-HCl, pH 7.4, 0.1 mM phenylmethylsulphonyl fluo-
ride (PMSF) and 0.1 mM EDTA) the cells were harvested with a
rubber policeman. The cell suspension was centrifuged (3000 g,
4°C for 3 min) and the supernatant discarded. The packed cell
volume was measured and 1 ml pellet was resuspended in 9 ml
ice-cold buffer A. Cells were homogenized with a polytron
(6  ´ 30 s, setting 6). The crude homogenate was centrifuged for
10 min (3500 g at 4°C) in a Sorvall centrifuge and the supernatant
was centrifuged for 30 min at 40 000 g at 4°C. The resulting
membrane pellet was resuspended in 3 ml ice-cold buffer B
(50 mM Tris-HCl, pH 7.4 and 0.1 mM PMSF). Aliquots of
membranes were stored at –80°C and they will retain their
saturable [3H]-vinblastine binding activity for at least a year
(Ferry et al, 1995). Protein concentrations were measured with a
Bio-Rad kit using bovine serum albumin as a standard.
Gel electrophoresis and Western blotting
A 6% sodium dodecyl sulphate (SDS) gel (Sambrook et al, 1989)
was loaded with 10–100 mg membrane protein after denaturation
with gel sample buffer and run at 12 mA overnight. The protein
was transferred over 4 h onto a nitro-cellulose blotting membrane.
Non-specific binding was blocked with 5% milk powder in PBS
and Tween. Incubation with the primary monoclonal antibody
NCL-JSB-1 (1:500 in 5% milk in PBS/Tween) lasted 16 h at 4°C.
The secondary antibody, mouse peroxidase IgG (1:1000 in 5%
milk in PBS/Tween), was added for 1 h and the protein was
visualized using the ECL protein detection reaction.
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Membrane binding assay
Binding of [3H]-vinblastine to membrane preparations was
performed as previously described (Ferry et al, 1992). Briefly,
50 ml buffer B (50 mM Tris-HCl, pH 7.4 and 0.1 mM PMSF), 50 ml
drug diluted in buffer B, 50 ml [3H]-vinblastine (5–7 nM) were
incubated with 100 ml membrane preparation (protein concentra-
tion 50–60 mg per assay) for 3 h in near darkness at 21°C. The total
assay volume was 0.25 ml. The assay was stopped by adding
3.5 ml ice-cold washbuffer (20 mM Tris–HCl, pH 7.4 and 20 mM
MgCl2) followed by rapid filtration through a Whatman GF/C
filter (pre-wetted with 50 mM Tris–HCl and 0.1% albumin) to
separate bound from free radioactivity. The filter was washed
twice with 5 ml washbuffer to remove free radioactivity, dried and
added to scintillation vials filled with 3 ml scintillant. Retained,
bound radioactivity was measured with a liquid scintillation
counter.
Rhodamine dye accumulation and efflux assay
measured by FACS analysis
The rhodamine (Rh123) dye accumulation assay was performed
as previously described (Davies et al, 1996). Briefly, 1 ´ 106
MES-SA or MES-Dx5 cells were seeded into 55-mm Petri dishes
and allowed to become adherent overnight at 37°C. The medium
was replaced with 5 ml additive free medium and incubated with
0.4 mM Rh123 for 20 min at 37°C in darkness. The cells were
washed with PBS (37°C). Control cells were harvested before the
dye could efflux. Additive free medium was added to the other
samples and the cells were incubated for 1.5 h at 37°C. Cells were
harvested with trypsin–EDTA at 4°C. Following centrifugation
(3000 g, 4°C for 3 min) the cell pellet was washed in ice-cold
PBS and resuspended in 1 ml ice-cold PBS and propidium iodate
(5 mg ml–1), incubated for 10 min on ice followed by a wash in
ice-cold PBS and centrifugation (3000 g, 4°C for 3 min). The cells
were fixed for 20 min in 1 ml 1% paraformaldehyde (in PBS).
Flow cytometric analysis of the paraformaldehyde fixed cells
was carried out by FACScan flow cytometer with an excitation
wavelength of 488 nm. R123 and propidium iodate fluorescence
were determined for 15 000 cells, considering only viable cells
(PI-excluding cells). Fluorescence data were shown on a three-
decade log scale.
Data analysis
All cytotoxicity data were modelled by non-linear regression using
Kaleidagraph (Ablebeck Software, USA). Dose–response curves
for cytotoxicity of drugs in absence or presence of the P-gp
inhibitor GF120918 were analysed by non-linear curve fitting,
using measured absorption of formazan produced by viable cells at
550 nm wavelength. Data were modelled with the general
dose–response equation (DeLean et al, 1981):
Y = ((a – d) / (1+ [X / C]b)) + d
where Y is the absorption of formazan salts produced by viable
cells at a molar concentration of cytotoxic drug X. The maximum
of the curve is a, the minimum is d, the slope factor is b and C the
drug concentration which inhibits the cell proliferation by 50%.
For most curves a, b, C and d were the modelled parameters.
The effect of GF120918 to sensitize MES-Dx5 cells to cytotoxic
drugs was expressed as % maximal shift of resistance, using the
following formula:
EC50R4EC50(R+I)
=[] 3100
EC50R4EC50(R+Imax conc)
with the EC50, the concentration of the cytotoxic drug required to
inhibit cell proliferation by 50% for R the resistant cell line MES-
Dx5, S the sensitive cell line MES-SA and I the P-gp inhibitor
GF120918 at various concentrations. Ligand binding experiments
were analysed by non-linear curve fitting as previously described
(Malkhandi et al, 1995).
Means from independent experiments (n) are given with stan-
dard errors of mean, s.e.m. Statistical significance was analysed
with the t-test.
RESULTS
Reversal of MES-Dx5 resistance to cytotoxics by
GF120918
The wild-type MES-SA cells were subjected to a 3-day exposure
to various cytotoxic agents and cell viability was assessed with the
formazan-based MTT assay. The MES-SA cells were sensitive to
vinblastine, taxotere and taxol with an EC50 of 3 ± 1n M (n = 4),
5 ± 1n M (n = 2) and 5 ± 1n M (n = 5) respectively, less sensitive to
doxorubicin with an EC50 of 58 ± 14 nM (n = 5) and etoposide with
an EC50 of 3003 ± 1006 nM (n = 5) (Table 1 and Figure 2 A–E).
The doxorubicin selected cell line MES-Dx5 exhibited the
following resistance pattern compared to the parental cell line
MES-SA: taxol 94-fold, taxotere 19-fold, vinblastine tenfold,
doxorubicin ninefold and etoposide twofold resistance (Table 1
and Figure 2 A–E). One striking feature of these dose–response
curves is the variation in the steepness of the slope, a topic usually
ignored in the literature.
Table 1 EC50 (nM) of cytotoxic drugs in MES-SA and MES-Dx5 cells (MTT dye-based cytotoxicity assay after 72-h exposure to drugs) and resistance factor for
MES-Dx5 cells.
Drug MES-SA MES-Dx5
EC50 (nM) Slope n EC50 (nM) Slope n RFa
Etoposide 3003 ± 1006 0.4 ± 0.1 5 6846 ± 504 1.0 ± 0.2 3 2
Doxorubicin 58 ± 14 0.9 ± 0.2 5 534 ± 67 0.9 ± 0.1 13 9
Vinblastine 3 ± 1 1.6 ± 0.3 4 30 ± 12 0.6 ± 0.1b 61 0
Taxotere 5 ± 0.1 2.6 ± 0.1 2 93 ± 28 0.5 ± 0.1c 21 9
Taxol 5 ± 1 2.0 ± 0.2 5 470 ± 98 0.5 ± 0.1c 89 4
aResistance factor; bP = 0.0003 slope MES-Dx5 vs MES-SA cells; cP < 0.0001 slope MES-Dx5 vs MES-SA cells.Potent P-glycoprotein inhibitor GF120918 945
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In MES-Dx5 cells a low slope was observed for the dose–
response curve of all tubulin inhibitors (vinblastine < taxol <
taxotere) (Table 1) compared to (i) doxorubicin and etoposide
or (ii) the dose–response curves in MES-SA cells. The
dose–response curves for taxanes in particular had slope factors of
< 1.0 (P < 0.0001), implying that proportional increases in the
doses of taxanes have less effect than for drugs with steep
dose–response curves such as doxorubicin.
The addition of the P-gp inhibitor GF120918 (100 nM) for 72 h
did not affect sensitivity of the parental MES-SA cells to any of
the five cytotoxics tested (results not shown). GF120918 alone did
not produce a cytotoxic effect during the 72-h exposure in the
MTT assay. An example of the sensitizing effect of GF120918 for
taxol in MES-Dx5 cells is shown in Figure 3A. GF120918 concen-
trations of greater than 10 nM steepened the dose–response curves
for taxol, vinblastine and taxotere. GF120918 was able to fully
reverse resistance of the MES-Dx5 cells to the level of drug sensi-
tivity shown by the parental MES-SA cells for all tested cytotoxic
drugs. Based upon the analysis undertaken, the EC50 of GF120918
to sensitize MES-Dx5 cells to taxol was 91 ± 23 nM (n = 8) but
7 ± 2n M (n = 3) for etoposide (Table 2, Figure 3 B, C). The
relative resistance to each cytotoxic agent correlated with the
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quadruplicate946 HCL Traunecker et al
British Journal of Cancer (1999) 81(6), 942–951 © 1999 Cancer Research Campaign
GF120918 concentration needed to restore 50% of sensitivity
(r = 0.9, P = 0.03). To test if this observation is due to P-gp in
MES-Dx5 cells or the effect of GF120918, we have performed
reversal experiments with another P-gp inhibitor, verapamil, in
MES-Dx5 cells which modulated resistance to taxol, doxorubicin,
vinblastine and etoposide equipotently with an EC50 of ~3 mM
(Figure 3D).
[3H]-vinblastine, [3H]-taxol and [14C]-doxorubicin
accumulation assays
The non-P-gp expressing MES-SA cells accumulated [3H]-
vinblastine, [3H]-taxol and [14C]-doxorubicin in a time-dependent
manner. MES-Dx5 cells accumulated radiolabelled drugs with
a similar time course, but accumulated 20% less [3H]-taxol,
20% less [14C]-doxorubicin and 35% less [3H]-vinblastine at
steady state. GF120918 did not increase the cellular content of
Table 2 Concentrations of GF120918 required to shift sensitivity of MES-
Dx5 cells to cytotoxic drugs by 50% and to reverse accumulation deficits by
50%
Drug [GF120918], nM, [GF120918], nM,
shifts sensitivity by 50%a reverses accumulation-deficit
by 50%b
Etoposide 7 ± 2c,d N/A
Doxorubicin 21 ± 6 64 ± 21
Vinblastine 19 ± 3c 48 ± 6
Taxotere 57 ± 14 N/A
Taxol 91 ± 24 37 ± 3
aCalculation of EC50 of GF120918 which caused a 50% increase in sensitivity
as assessed by cytotoxicity assay (MTT) is described in Materials and
Methods. See Figure. 3A for an example of a representative experiment.
bRadiolabelled cytotoxic drug accumulation assay were performed as
described in Materials and Methods. Actual dose–response curves are
shown in Figure 5. cP < 0.05 taxol vs other drug. dP < 0.05 taxotere vs other
drug.
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radiolabelled cytotoxics in the sensitive MES-SA cells (data not
shown). However in MES-Dx5 cells, at a saturating concentration
of 1 mM, GF120918 increased the cellular accumulation of all three
drugs by 30% at 4 h. In MCF-7/ADR cells, a breast cancer cell line
selected in doxorubicin with sixfold higher expression of P-gp,
1 mM GF120918 increased the uptake of [14C]-doxorubicin by
240% (data not shown).
A dose-dependent effect of GF120918 existed for all three
radiolabelled cytotoxic drugs (Figure 4). The EC50 for the reversal
of the accumulation deficit by GF120918 in MES-Dx5 cells
ranged from 37–64 nM (Table 2).
Gel electrophoresis and Western blotting of membrane
preparations
The monoclonal antibody NCL-JSB-1 could detect P-gp in
Western blots of membranes prepared from MES-Dx5 cells (limit
of detectability 10 mg membrane protein) but did not in MES-SA
membranes. The calculated molecular weight for P-gp in MES-
Dx5 cells was 156 kDa (data not shown).
FACS analysis of P-gp expression
FACS analysis of rhodamine accumulation and its efflux was used
to determine if the MES-Dx5 cells consisted of more than one
population. MES-Dx5 cells were found to consist of a single-cell
population with regard to rhodamine efflux (Figure 5).
Membrane binding assay
Saturation analysis of [3H]-vinblastine binding in MES-Dx5 cell
membrane preparations revealed a Bmax of 5.2 ± 1.6 pmol mg–1
protein and a KD of 6.8 ± 1.4 nM. The addition of ATP and MgCl2
had only a minor effect on [3H]-vinblastine binding (Figure 6).
[3H]-vinblastine binding to membrane preparations of MES-SA
was not displaceable by cyclosporin A (Figure 7A), a well
described, competitive inhibitor of [3H]-vinblastine binding to
P-gp (Ferry et al, 1992). Cyclosporin A displaceable [3H]-vin-
blastine binding to P-gp in MES-Dx5 membrane preparations was
proportional to the amount of protein used (up to 300 mg).
Cyclosporin A inhibited [3H]-vinblastine binding to P-gp to the
level of non-specific binding in MES-SA cells.
Inhibition of [3H]-vinblastine binding to MES-Dx5 membranes
was assessed using several cytotoxic agents and P-gp inhibitors.
Doxorubicin was a weak inhibitor with a Ki = 6940 ± 2100 nM
followed in increasing potency by verapamil (Ki = 660 ± 350 nM),
taxol (Ki = 400 ± 135 nM) and GF120918 (Ki = 5 ± 1n M) (Figure
7B). Taxol, an allosteric inhibitor of [3H]-vinblastine binding
(Ferry et al, 1994), could displace only 40% of [3H]-vinblastine
bound to P-gp.
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A narrow, single peak indicated a single population of P-gp expressing cells.
The results of a representative experiment are shown
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Figure 6 Saturation isotherm of [3H]-vinblastine binding to MES-Dx5
membrane preparations. Membrane preparation of MES-Dx5 (42 mg protein
per assay) was incubated with 0.5–33 nM [3H]-vinblastine and 3 mM
vinblastine over 3 h (• •). A total of 1 mM ATP and 3 mM MgCl2 were added
as indicated (•). Vinblastine binding to P-gp in MES-Dx5 cells achieved a
Bmax = 8.6 ± 0.4 pmol mg–1 protein and a K D = 8.7 ± 0.7 nM. In the presence
of ATP and MgCl2 the modelled parameters were Bmax = 10.9 ± 2.1 pmol mg–1
protein and a KD = 10.3 ± 3.4 nM. Data shown are from a single
representative experiment done in duplicate948 HCL Traunecker et al
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Effect of a high concentration of fetal calf serum on the
potency of GF120918 in MCF-7/ADR cells
MES-Dx5 cells grew poorly in medium supplemented with 50%
FCS. Therefore MCF-7/ADR cells and their drug-sensitive wild-
type MCF-7 cells were used to explore the effect of a high protein
concentration on the potency of GF120918 (MTT assay). The cells
were incubated with the cytotoxic drug taxol in the presence of a
series of potent P-gp inhibitors and either 10% or 50% FCS. The
data are shown in Table 3. Although all P-gp inhibitors were less
potent in 50% FCS, this effect was significantly smaller (P < 0.05,
t-test) for GF120918 (2.6 ± 1.5-fold) compared to CP100356
(88 ± 22-fold), dexniguldipine (37 ± 9-fold), CGP 412251
(30  ± 12-fold) or PSC833 (19 ± 6-fold).
DISCUSSION
MES-Dx5 cells were derived from a human uterine sarcoma cell
line, MES-SA after long-term selection in 500 nM doxorubicin
(Harker et al, 1983; Harker and Sikic, 1985). The resistance factors
to doxorubicin, vinblastine and etoposide in the 72-h MTT cyto-
toxicity assay we report were lower than those previously reported
for the 1-h drug exposure in a colony-forming assay (Harker and
Sikic, 1985). This is not surprising for tubulin-binding drugs and
etoposide which show marked cell-cycle/phase dependency. After
a 72-h exposure of MES-Dx5 cells to cytotoxic drugs, a resistance
pattern similar to the one we have observed has been described
(Gosland et al, 1989).
MES-Dx5 cells expressed P-gp as assessed by Western blotting
and [3H]-vinblastine binding, which allowed quantification of the
number of P-gp molecules per mg protein. In the drug sensitive
clone MES-SA P-gp could not be detected by either method. The
density of [3H]-vinblastine binding sites in MES-Dx5 membrane
preparations was about 25% that of MCF-7/ADR cells (Ferry et al,
1995). This correlates with the higher resistance of MCF-7/ADR
cells to e.g. doxorubicin (200-fold) and taxol (1000-fold) (MA
Russell and DR Ferry, unpublished data).
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Figure 7 [3H]-vinblastine binding studies using cell surface membrane preparations of MES-SA and MES-Dx5 cells. (A) Cell surface membrane preparations
(9–300 mg protein) were incubated with 7.6 nM [3H]-vinblastine (Bo) and 10 mM cyclosporin A (B1) for 2 h. MES-SA cells exhibited only non-specific binding of
[3H]-vinblastine. Binding of [3H]-vinblastine to MES-Dx5 membranes increased in a protein dependent manner up to 300 mg protein. Cyclosporin A inhibited
[3H]-vinblastine binding to P-gp to the level of non-specific binding in MES-SA cells. (B) Inhibition of [3H]-vinblastine binding to P-gp in MES-Dx5 membrane
preparations by cytotoxic agents and P-gp inhibitors. Membrane preparations were incubated with 5 nM [3H]-vinblastine and doxorubicin (´), taxol (• •), verapamil
(•) or GF120918 (u u) over 3 h. The Ki values were as follows: doxorubicin = 112 mM, taxol = 96 nM, verapamil = 1.7 mM and GF120918 = 5 nM. Data shown are
from a single representative experiment done in duplicate
Table 3 Effect of protein binding on the potency of P-gp inhibitors using the EC50 (nM) of taxol in P-gp-expressing
MCF-7/ADR cells and the wild-type MCF-7 WT cells (MTT dye based cytotoxicity assay after 72-h exposure to drugs)
Drug 10% FCS 50% FCS Ratio of EC50sa
EC50, nM n EC50, nM n
None (MCF-7/WT) 6 ± 23 5   ± 3 3 0.84
Noneb 8500 ± 1400 8 4600 ± 800 12 0.54c
GF120918 (0.1 mM)b 8 ± 2 3 22 ± 5 3 2.6 ± 1.5
PSC 833 (2 mM)b 52 ± 22 3 980 ± 210 3 19 ± 6d
CGP 41251 (2 mM)b 102 ± 56 3 3055 ± 400 3 30 ± 12d
Dexniguldipine (1 mM)b 35 ± 8 3 1290 ± 37 3 37 ± 9d
CP100356 (1 mM)b 81 ± 20 3 7120 ± 1800 3 88 ± 22d
aCalculated with the formula Equation 3. bP-gp expressing MCF-7/ADR cells. cP < 0.05 EC50 50% FCS vs EC50 10% FCS;
dP < 0.05 ratio of EC50s for GF120918 vs other inhibitors.One striking feature of the dose–response curves of the cyto-
toxic drugs in MES-Dx5 cells was the variation in their slopes.
Thus the slopes of the dose–response curves for taxanes and
vinblastine were significantly lower than for doxorubicin. When
the P-gp inhibitor GF120918 (Hyafil et al, 1993), an acridone-
carboxamide, was added to these cells, the slopes of the
dose–response curves for taxanes and vinblastine became steeper,
reaching the same level as those observed in the parental MES-SA
cells.
One possible explanation for this phenomenon could be, that
MES-Dx5 cells consisted of two or more populations of cells
expressing different amounts of P-gp. However, in a rhodamine
FACS analysis (using the method described by Davies et al
(1996)), a single population of MES-Dx5 cells was detected. Other
explanations needed to be further considered, including hetero-
geneity of tubulin expression due to mutations in microtubules.
Mutations in tubulin subunits were described in a series of mutant
Chinese hamster ovary cell lines which rendered the cells resistant
to taxol (Schibler and Cabral, 1986). Assuming the level of resis-
tance to taxol in MES-Dx5 cells was due to the combined effects
of P-gp and mutated microtubulin, the inhibition of P-gp should
only lead to a shift of the dose–response curve to the left, e.g.
concentrations of cytotoxic drugs achieve higher level of cytotoxi-
city but not to an alteration in the steepness of the dose–response
curve. This was clearly not the case since the P-gp inhibitor
GF120918 fully sensitized MES-Dx5 and additionally increased
the slope of the dose–response curve for all tubulin binding drugs,
taxol, taxotere and vinblastine.
MES-Dx5 cells were fully sensitized to a variety of natural
product cytotoxics with nM concentrations of the recently
described potent P-gp inhibitor GF120918, achieving the same
sensitivity as the parental MES-SA cells. GF120918 acted potently
on P-gp with concentrations as low as 1nM, exhibiting a measur-
able reversal of resistance in the MTT assay. However, fivefold
higher concentrations of GF120918 were required to reverse resis-
tance to taxol by 50% compared to doxorubicin and vinblastine.
Similarly an eightfold higher concentration of GF120918 was
required to reverse resistance to taxotere by 50% compared to
etoposide. If GF120918 bound to a common site, ‘plugging’ P-gp,
the EC50 to reverse resistance expressed in the cytotoxicity assay
and the EC50 to increase the cellular accumulation of drugs, should
be equal. A number of possible explanations for this phenomenon
are discussed below.
The potency of GF120918 to reverse resistance relates to
the affinity of cytotoxics to bind to P-gp
We know that [3H]-GF120918 can bind saturably and with a
0.8nMKD to human P-gp (Ferry et al, 1996). Theoretically the
explanation may lie in the relative affinities of the cytotoxic drugs
for P-gp. Thus, if drug A (e.g. taxol or vinblastine) has a very high
affinity for P-gp relative to drug B (e.g. doxorubicin or etoposide)
and both are present at equal concentrations, more GF120918 will
be needed to inhibit the binding of drug A by 50%. However, there
was no clear relationship between the potency to modulate a given
cytotoxic drug and the affinity to bind to P-gp. Furthermore, since
the EC50 for GF120918 to reverse drug resistance was higher for
taxol than for vinblastine this explanation must be flawed. These
observations therefore imply that P-gp cannot be regarded as a
simple receptor at which drugs compete.
The potency of GF120918 to reverse resistance relates to
binding affinities for different P-gp drug acceptor sites.
Accepting that taxol and GF120918 both bind to P-gp, one
possibility is that GF120918 has a lower affinity for a taxane-
selective binding domain of P-gp. This would be revealed by
higher concentrations of GF120918 required to reverse the
[3H]-taxol accumulation deficit. However the EC50 of GF120918
to reverse the [3H]-taxol accumulation deficit was 37 ±3nMand
not significantly higher than for the other drugs.
One reason for the failure of the above model to explain why
GF120918 is less potent in modulating resistance to taxol and
taxotere compared to the other cytotoxic drugs may be that the
assumptions underlying the models are incorrect. The mechanisms
of permeation of P-gp by cytotoxics is poorly characterized. The
initial rate of transport and turnover numbers of P-gp are not
known for any substrate.
The model assumes that GF120918, taxol and the other drugs
bind to a common drug acceptor site of P-gp. Whilst previous data
was interpreted as suggesting that P-gp has a unitary drug acceptor
site (Raviv et al, 1990), more recent data suggest that P-gp has
more than one drug acceptor site which may even be allosterically
coupled (Spoelstra et al, 1992; Ferry et al, 1994; Boer et al, 1996;
Day et al, 1997).
Thus if GF120918 has a lower affinity for the taxol drug
acceptor site versus that for vinblastine, the potency to modulate
resistance would be lower. This remains to be tested using
[3H]-GF120918 as a radioligand in binding studies.
The effect of other membrane drug transporters
Resistance to etoposide and doxorubicin can be conferred by the
expression of the multidrug-resistance associated protein, MRP1
(Cole et al, 1992), a membrane transporter protein. Both, the wild-
type MES-SA cells and the P-gp-positive clone MES-Dx5 express
similar levels of MRP1 (Chen et al, 1994). Additionally, it was
demonstrated that the lung cancer cell line COR-L23 R (Barrand et
al, 1994), which expresses MRP1 but not P-gp, was not sensitized
to doxorubicin by 1mM GF120918 (HCL Traunecker and DR
Ferry, unpublished data). Therefore, the effect of GF120918 is
unlikely to be due to the inhibition of MRP1.
The major vault protein, LRP, a transporter protein present in
vesicular membranes has been implicated in resistance to doxo-
rubicin (Scheper et al, 1993). Although LRP has been detected in
parental MES-SA cells, no expression was detectable in the MES-
Dx5 cells (Chen et al, 1994).
The resistance factor correlates with the concentration of
GF120918 required to modulate the resistance
The striking correlation between the EC50 of GF120918 to reverse
resistance in the cytotoxicity assay and the resistance factor of
each cytotoxic agent (r= 0.9) suggests that the potency of
GF120918 relates closely with the resistance factor of the cyto-
toxic drug. This implies, that a given concentration of GF120918
induces a given fractional modulation of resistance. It is difficult to
envisage how this could occur at the molecular level.
Although there is no direct evidence, it is mechanistically plau-
sible that GF120918 is a more potent modulator of resistance to
vinblastine, doxorubicin and etoposide than the taxanes probably
as a consequence of the pattern of binding to P-gp and subsequent
inhibition of substrate transport by P-gp in MES-Dx5 cells.
Experiments aimed at measuring direct binding of [3H]-taxol and
Potent P-glycoprotein inhibitor GF120918949
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[3H]-GF120918 to P-gp may cast some light and give some clues
as to the molecular mechanisms underlying the phenomenon
observed in the cytotoxicity assays.
GF120918 is the most potent P-gp inhibitor described (Hyafil
et al, 1993) and retains most of its activity at high protein
concentrations (50% FCS). All other tested P-gp inhibitors,
i.e. CP100356, dexniguldipine, CGP 412251 and PSC833 were
significantly less potent in the presence of 50% FCS. This finding
is important for clinical studies in view of the high protein concen-
trations present in whole blood. In this manuscript detailed phar-
macological data regarding the reversal of resistance to
vinblastine, doxorubicin, etoposide, taxotere and taxol by
GF120918 have been documented for the first time. The results
have significant implications on a number of levels. Functional
studies of P-gp, particularly binding and transporting of cytotoxic
agents and P-gp inhibitors are not yet sophisticated enough to esti-
mate initial rates of transport or turnover rates for any substrate.
The relatively low expression of P-gp in cells was a major problem
which some groups recently overcame by purifying P-gp (Shapiro
et al, 1995; Callaghan et al, 1997). This may allow to re-address
these fundamental questions in the future.
GF120918 has entered phase I clinical trials in combination
with doxorubicin (Ferry et al, 1998; Planting et al, 1998). The
serum levels achieved are known to reverse the P-gp mediated
efflux of rhodamine in CD56 cells (natural killer cells) in normal
volunteers (Kerr et al, 1996) and the full trial data will be
presented soon (Ferry et al, in preparation).
In terms of the future clinical application, it may prove impor-
tant that the resistance to doxorubicin could be modulated at lower
concentrations of GF120918 compared to the taxanes, taxol and
taxotere but remains to be tested.
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